Delineation of the Diabetogenic Role of Extrapancreatic Glucagon in Totally Pancreatectomised Patients Using Glucagon Receptor Antagonism

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 Nov 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Oct 2023 Status changed from recruiting to completed according to results presented at the 59th Annual Meeting of the European Association for the Study of Diabetes.
06 Oct 2023 Results (n=18) assessing the effect of chronic pancreatic glucagon depletion and acute glucagon receptor antagonism, respectively, on FGF21 levels presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
26 Jun 2023 Results (n=18) assessing the effect of chronic pancreatic glucagon depletion and acute glucagon receptor antagonism on FGF21 levels presented at the 83rd Annual Scientific Sessions of the American Diabetes Association

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com